LH · Labcorp Holdings Inc.

$318.13 -4.46 (-1.38%) At close · Aug 14

Market Cap

$25.80B

81.10M

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.

Insider Sentiment Score

Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.

Net buyers

-2

Net shares bought

0.00%

Net buy value

-$722,535

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-08-11	Schechter Adam H	Director, President & CEO	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	4,669	$320.37	$1,495,808	102,565
2026-08-04	Summy Amy B.	EVP, Chief Marketing Officer	Sell↓	Common Stock	924	$306.74	$283,428	6,955
2026-08-03	Wilkinson Peter J	SVP, Chief Accounting Officer	Sell↓	Common Stock	82	$309.22	$25,356	1,770
2026-08-03	Wilkinson Peter J	SVP, Chief Accounting Officer	Convert↓ Filing footnotes — Non-qualified Stock Options (Direct) Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea. The options vested in three equal annual installments beginning on the date reflected in this column and are now fully exercisable.	Non-qualified Stock Options	1,338	—	—	0
2026-08-03	Wilkinson Peter J	SVP, Chief Accounting Officer	Sell↓	Common Stock	1,338	$309.23	$413,751	1,770
2026-08-03	Wilkinson Peter J	SVP, Chief Accounting Officer	Convert↑	Common Stock	1,338	$209.25	$279,977	3,108
2026-07-02	Vaughn Bryan T	EVP, Diagnostics	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	234	$286.19	$66,968	6,745
2026-07-02	Kyle Kathryn W	EVP, Chief Legal Officer	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	92	$286.19	$26,329	3,904
2026-07-01	Vaughn Bryan T	EVP, Diagnostics	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	93	$283.88	$26,401	6,979
2026-07-01	Vaughn Bryan T	EVP, Diagnostics	Convert↓ Filing footnotes — Restricted Stock Unit (Direct) Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.	Restricted Stock Unit	327	—	—	3,704
2026-07-01	Kyle Kathryn W	EVP, Chief Legal Officer	Convert↑ Filing footnotes — Common Stock (Direct) Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.	Common Stock	256	—	—	4,069
2026-07-01	Vaughn Bryan T	EVP, Diagnostics	Convert↑ Filing footnotes — Common Stock (Direct) Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.	Common Stock	327	—	—	7,072
2026-07-01	Kyle Kathryn W	EVP, Chief Legal Officer	Convert↓ Filing footnotes — Restricted Stock Unit (Direct) Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.	Restricted Stock Unit	256	—	—	2,008
2026-07-01	Kyle Kathryn W	EVP, Chief Legal Officer	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	73	$283.88	$20,723	3,996
2026-06-08	Kyle Kathryn W	EVP, Chief Legal Officer	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	762	$263.89	$201,084	3,813
2026-05-11	Schechter Adam H	Director, President & CEO	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	5,903	$254.50	$1,502,314	107,234
2026-03-27	Meltzer Jonathan C	EVP, Operations	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	839	$267.05	$224,055	3,620
2026-03-27	Wilkinson Peter J	SVP, Chief Accounting Officer	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	1,633	$267.05	$436,093	1,852
2026-03-26	van der Vaart Sandra D	Director, President and Secretary	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	2,722	$268.38	$730,530	6,238
2026-03-26	Schroeder Mark S	EVP, Pres Diagnostics & COO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	2,968	—	—	14,145
2026-03-26	Caveney Brian J	EVP, Pres of ED, CMO & CSO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	4,042	$268.38	$1,084,792	35,368
2026-03-26	Bailey Megan D.	EVP, Pres, Central Labs & Intl	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	1,184	—	—	5,332
2026-03-26	Schroeder Mark S	EVP, Pres Diagnostics & COO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	9,304	—	—	15,777
2026-03-26	Summy Amy B.	EVP, Chief Marketing Officer	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	3,994	—	—	9,715
2026-03-26	GRAHAM ANITA Z	EVP, CHRO & Public Affairs	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	2,879	$268.38	$772,666	5,185
2026-03-26	Oyegunwa Akinbolade	EVP, CIO & CTO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	1,340	—	—	5,446
2026-03-26	Bailey Megan D.	EVP, Pres, Central Labs & Intl	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	481	$268.38	$129,091	4,851
2026-03-26	Vaughn Bryan T	EVP, Diagnostics	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	1,584	—	—	7,196
2026-03-26	Wilkinson Peter J	SVP, Chief Accounting Officer	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	2,388	—	—	4,240
2026-03-26	GRAHAM ANITA Z	EVP, CHRO & Public Affairs	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on April 5, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	6,604	—	—	8,064
2026-03-26	Kyle Kathryn W	EVP, Chief Legal Officer	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	1,584	—	—	5,026
2026-03-26	Schechter Adam H	Director, President & CEO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	58,470	—	—	139,243
2026-03-26	Schroeder Mark S	EVP, Pres Diagnostics & COO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	4,600	$268.38	$1,234,548	11,177
2026-03-26	Schroeder Mark S	EVP, Pres Diagnostics & COO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	1,468	$268.38	$393,982	12,677
2026-03-26	Oyegunwa Akinbolade	EVP, CIO & CTO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	382	$268.38	$102,521	5,064
2026-03-26	Caveney Brian J	EVP, Pres of ED, CMO & CSO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	863	$268.38	$231,612	36,491
2026-03-26	Meltzer Jonathan C	EVP, Operations	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	711	$268.38	$190,818	4,459
2026-03-26	Caveney Brian J	EVP, Pres of ED, CMO & CSO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	1,986	—	—	37,354
2026-03-26	Vaughn Bryan T	EVP, Diagnostics	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	451	$268.38	$121,039	6,745
2026-03-26	Wilkinson Peter J	SVP, Chief Accounting Officer	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	755	$268.38	$202,627	3,485
2026-03-26	Schechter Adam H	Director, President & CEO	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	26,106	$268.38	$7,006,328	113,137
2026-03-26	van der Vaart Sandra D	Director, President and Secretary	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	6,382	—	—	8,960
2026-03-26	Meltzer Jonathan C	EVP, Operations	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	2,388	—	—	5,170
2026-03-26	Summy Amy B.	EVP, Chief Marketing Officer	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	1,836	$268.38	$492,746	7,879
2026-03-26	Kyle Kathryn W	EVP, Chief Legal Officer	Tax↓ Filing footnotes — Common Stock (Direct) Stock withholding to satisfy tax withholding obligations.	Common Stock	451	$268.38	$121,039	4,575
2026-03-26	Caveney Brian J	EVP, Pres of ED, CMO & CSO	Award↑ Filing footnotes — Common Stock (Direct) Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.	Common Stock	9,304	—	—	39,410
2026-03-03	Schechter Adam H	Director, President & CEO	Sell↓	Common Stock	8,705	$279.96	$2,437,047	80,773
2026-02-27	van der Vaart Sandra D	Director, President and Secretary	Sell↓	Common Stock	547	$284.91	$155,846	2,578
2026-02-24	Caveney Brian J	EVP, Pres of ED, CMO & CSO	Sell↓	Common Stock	1,500	$286.31	$429,458	30,106
2026-02-19	Wilkinson Peter J	SVP, Chief Accounting Officer	Sell↓ Filing footnotes — Common Stock (Direct) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.	Common Stock	666	$277.94	$185,108	1,852

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–50 of 1,472 transactions

Key facts CIK 920148 CUSIP 504922105 13F (30d) 962 filings 925 filers Visit website Investor relations